Showing posts with label Adults. Show all posts
Showing posts with label Adults. Show all posts
Tuesday, July 28, 2026

FDA Approves Komzifti (ziftomenib) for the Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

›
Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151)  announced the U.S. Food and Drug Administration (FDA)   approval o...
Friday, July 24, 2026

FDA Approves Cardamyst (etripamil) Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

›
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced  the U.S. Food and Drug Administration (FDA) approved its first commercial product, ...
Wednesday, July 22, 2026

FDA Approves Myqorzo (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

›
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the U.S. Food and Drug Administration (FDA) approval of  Myqorzo™ (aficamten, 5 mg, 10 m...
Tuesday, July 21, 2026

FDA Approves Aqvesme (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

›
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for pati...
Monday, November 3, 2025

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

›
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)   announced   U.S. Food and Drug Administration (FDA)   approval of  Journavx (suzetrigin...
Wednesday, July 24, 2024

FDA Approves Ogsiveo (nirogacestat) for Adults with Desmoid Tumors

›
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, anno...
Friday, September 30, 2022

FDA Approves Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder in Adults

›
            dextromethorphan   Bupropion In continuation of my updates on dextromethorphan and Bupropion ,  Axsome Therapeutics, Inc. , a...
Wednesday, March 9, 2022

FDA Approves Quviviq (daridorexant) for the Treatment of Adults with Insomnia

›
Idorsia Ltd (SIX: IDIA) announced  the US Food and Drug Administration (FDA)  approval of   Quviviq  (daridorexant) 25 mg and 50 mg for the ...
Monday, March 7, 2022

FDA Approves Cibinqo (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

›
Pfizer Inc. (NYSE: PFE) announced  the United States (U.S.) Food and Drug Administration (FDA) approval of   Cibinqo  (abrocitinib), an oral...
Thursday, January 14, 2021

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia

›
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved  Onureg  (azacitidine 300 mg tablet...
Saturday, March 21, 2020

FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults

›
In continuation of my update on pexidartinib U.S. Food and Drug Administration granted approval to  Turalio  (pexidartinib) caps...
Friday, March 20, 2020

FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes

›
In continuation of my updates on Semaglutide Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has appro...
Tuesday, January 7, 2020

FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults

›
U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptom...